<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02898025</url>
  </required_header>
  <id_info>
    <org_study_id>RLiebano</org_study_id>
    <nct_id>NCT02898025</nct_id>
  </id_info>
  <brief_title>Low Level Laser Therapy and Interferential Current in Osteoarthritis</brief_title>
  <official_title>Low Level Laser Therapy and Interferential Current in Patients With Knee Osteoarthritis: Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Cidade de Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Cidade de Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the effectiveness of the low level laser therapy and
      interferential current in 168 patients with knee osteoarthritis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interventional
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity measured by a numeric pain scale ranging from 0 to 10.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pressure Pain Threshold measured by a pressure algometer. Pressure will be recorded in kPa.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>TUG (Timed Up &amp; Go Test)</measure>
    <time_frame>Measure at baseline, 4 weeks, 3 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isokinetic Muscle Assessment</measure>
    <time_frame>Measure at baseline, 4 weeks, 3 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LeQuesne Questionnaire</measure>
    <time_frame>Measure at baseline, 4 weeks, 3 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC (Western Ontario and McMaster Universities Arthritis Index)</measure>
    <time_frame>Measure at baseline, 4 weeks, 3 months, 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>G1 (Active IFC and Active Laser)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G1) will receive the treatment of Active Interferential Current and Active Laser for 12 sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G2 (Active IFC and Placebo Laser)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G2) will receive the treatment of Active Interferential Current and Placebo Laser for 12 sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G3 (Placebo IFC and Active Laser)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G3) will receive Placebo Interferential Current and Active Laser for 12 sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G4 (Placebo IFC and Placebo Laser)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. The placebo group (G4) will receive Placebo Interferential Current and Placebo Laser for 12 sessions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active Interferential Current</intervention_name>
    <description>Involves the application of medium frequency alternating currents</description>
    <arm_group_label>G1 (Active IFC and Active Laser)</arm_group_label>
    <arm_group_label>G2 (Active IFC and Placebo Laser)</arm_group_label>
    <other_name>interferential therapy</other_name>
    <other_name>IFC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active Laser</intervention_name>
    <description>Involves the application of low level laser over the knee</description>
    <arm_group_label>G1 (Active IFC and Active Laser)</arm_group_label>
    <arm_group_label>G3 (Placebo IFC and Active Laser)</arm_group_label>
    <other_name>low level laser therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo Interferential Current</intervention_name>
    <description>It is a sham interferential therapy</description>
    <arm_group_label>G3 (Placebo IFC and Active Laser)</arm_group_label>
    <arm_group_label>G4 (Placebo IFC and Placebo Laser)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo Laser</intervention_name>
    <description>It is a sham laser therapy</description>
    <arm_group_label>G2 (Active IFC and Placebo Laser)</arm_group_label>
    <arm_group_label>G4 (Placebo IFC and Placebo Laser)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of osteoarthritis of the knee characterized by pain of mild or moderate
             intensity

          -  Radiographic evidence of grade 2 or 3 osteoarthritis based on the Kellgren and
             Lawrence radiographic entry criteria

          -  Patients with knee osteoarthritis (s) according to the ACR criteria

          -  VAS 3 to 8

          -  5 to 12 Lequesne

          -  No complaint of pain in other joints of the lower limbs

          -  Without neurological and cognitive disorders

          -  No loss of sensation in the lower limbs

          -  No surgery on the knee (s) in the last 6 months

          -  Pain symptoms for at least 6 months

          -  No infiltrations (s) knee (s) in the last 4 weeks

          -  No use of analgesics 4 hours before treatment

        Exclusion Criteria:

          -  Individuals younger than 18 and older than 80 years

          -  Complaints from other diseases of the lower limbs, knee prosthesis and / or hip joint
             instabilities and / or surgery in lower limbs, heart disease, uncontrolled
             hypertension and diabetes, coagulation disorders in anticoagulant therapy, pregnant
             women, fibromyalgia and individuals who can not perform isokinetic test who have
             difficulty performing the TUG, and those that are experiencing abnormal sensitivity to
             algometry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard E Liebano, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Cidade de Sao Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNICID</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>03071-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>September 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2016</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Cidade de Sao Paulo</investigator_affiliation>
    <investigator_full_name>Richard Eloin Liebano</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

